GERON CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.48 USD | -0.29% |
|
-8.66% | +64.93% |
| May. 03 | Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating | MT |
| May. 02 | Geron Shares Decline After Q1 Loss Widens | MT |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Geron Virtual R&D In...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.48
USD
Average target price
6.071
USD
Spread / Average Target
+74.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +64.93% | 2.06B | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- GERN Stock
- News Geron Corporation
- Transcript : Geron Corporation - Special Call
